A PCHRD-funded study probing virgin coconut oil as an anti-viral agent against COVID-19 is showing promising…
Posted by DOST PCHRD on Tuesday, October 6, 2020
Bumaba raw ng 60 hanggang 90% ang coronavirus count ng ilang pasyente matapos gamitan ng virgin coconut oil (VCO), ayon sa Philippine Council for Health Research and Development (PCHRD).
Mula noong Mayo ay nagsasagawa na ng clinical trials ang Department of Science and Technology (DOST) sa virgin coconut oil bilang agent ng suspected at probable COVID-19 cases sa Laguna.
“The results are very promising, as not only does it show that the VCO, by itself, can destroy the virus, but it also has a key mechanism in upregulating the immune response against COVID-19,” ani PCHRD executive director Dr. Jaime Montoya.
“Indeed, we look forward to the results of clinical trials on the various uses of VCO as an adjunct for the treatment of COVID-19,” dagdag ng opisyal.
Bukod sa nasabing resulta, nadiskubre rin daw ng mga nagsasaliksik ang mabuting epekto ng VCO compound sa cell survival.
Kaya naman daw kailangan pa ng patuloy na pag-aaral kung mas epektibo laban sa pagkalat ng virus ang mas maraming concectration ng VCO.
“There are still alternative solutions against COVID-19 aside from vaccines. Although further investigation is needed before we develop a possible prevention or treatment option, we aim to give Filipinos hope through our ongoing local research initiatives,” ani DOST Sec. Fortunato de la Peña.
Ang DOST-PCHRD ang naglaan ng pondo sa pag-aaral na pinangungunahan naman ni Dr. Fabian Dayrit ng Ateneo De Manila University.
Bukod sa trial site sa Laguna, nakatakda ring magsimula ang hiwalay na clinical trials ng VCO sa COVID-19 patients sa Philippine General Hospital.
Target ng Science department na makadiskubre ng iba pang alternatibong solusyon habang hinihintay ng buong mundo ang bakuna laban sa COVID-19.
Ang Food and Nutrition Research Institute, kasama ang University of the Philippines-Manila ay may hiwalay din na pag-aaral sa kakayahan ng VCO para mapalakas ang immune system ng tao.
“Results from these ongoing VCO Clinical trials will determine whether VCO can be used as adjunct therapy for COVID-19 patients,” nakasaad sa press release.
“Aside from facilitating the eventual conduct of the WHO vaccine clinical trials in the Philippines, the DOST-PCHRD is also supporting projects under its initiatives on Repurposing of Existing Drugs, Supplements and other Formulations, and Clinical Trials of Candidate Drugs to find viable treatment options against COVID-19.”
